Alliancebernstein L.P. grew its holdings in shares of Merus (NASDAQ:MRUS - Free Report) by 9.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 796,957 shares of the biotechnology company's stock after buying an additional 66,326 shares during the quarter. Alliancebernstein L.P. owned 1.16% of Merus worth $33,512,000 as of its most recent SEC filing.
A number of other hedge funds have also made changes to their positions in MRUS. Avior Wealth Management LLC bought a new stake in shares of Merus in the 4th quarter valued at approximately $76,000. MML Investors Services LLC bought a new stake in Merus during the third quarter valued at $206,000. Gordian Capital Singapore Pte Ltd raised its holdings in shares of Merus by 10.4% during the third quarter. Gordian Capital Singapore Pte Ltd now owns 5,000 shares of the biotechnology company's stock worth $250,000 after purchasing an additional 470 shares during the period. HighTower Advisors LLC lifted its position in shares of Merus by 10.9% in the 4th quarter. HighTower Advisors LLC now owns 8,020 shares of the biotechnology company's stock worth $337,000 after buying an additional 789 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new position in shares of Merus in the 4th quarter valued at about $347,000. Institutional investors and hedge funds own 96.14% of the company's stock.
Merus Stock Up 8.7 %
Shares of Merus stock traded up $3.35 during midday trading on Friday, hitting $41.97. The company's stock had a trading volume of 832,258 shares, compared to its average volume of 712,988. Merus has a 1-year low of $33.19 and a 1-year high of $61.61. The firm has a market capitalization of $2.90 billion, a P/E ratio of -10.63 and a beta of 1.02. The stock has a 50-day simple moving average of $43.65 and a 200-day simple moving average of $45.25.
Merus (NASDAQ:MRUS - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.41) EPS for the quarter, topping analysts' consensus estimates of ($0.89) by $0.48. The firm had revenue of $9.14 million during the quarter, compared to analyst estimates of $10.57 million. Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%. As a group, sell-side analysts predict that Merus will post -3.85 earnings per share for the current year.
Analysts Set New Price Targets
A number of equities analysts have issued reports on the stock. Needham & Company LLC reissued a "buy" rating and issued a $83.00 target price on shares of Merus in a report on Wednesday. Bank of America dropped their price objective on Merus from $73.00 to $70.00 and set a "buy" rating on the stock in a research note on Monday, March 10th. Guggenheim reaffirmed a "buy" rating and set a $109.00 target price on shares of Merus in a report on Friday, March 28th. Piper Sandler initiated coverage on shares of Merus in a research report on Thursday, February 13th. They issued an "overweight" rating and a $84.00 price target on the stock. Finally, William Blair restated an "outperform" rating on shares of Merus in a research report on Friday, February 28th. One investment analyst has rated the stock with a sell rating, fourteen have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Merus presently has an average rating of "Buy" and a consensus target price of $85.31.
Read Our Latest Stock Analysis on MRUS
About Merus
(
Free Report)
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.
Further Reading
Before you consider Merus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merus wasn't on the list.
While Merus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
